Lila Sciences Revenue, Valuation, Funding & Investors

Lila Sciences is valued at $1.3B as of October 2025, a 17.3x multiple on its last reported $75M revenue.

Last Lila Sciences valuation

$1.3B

Series A · Oct 2025

Last Lila Sciences funding round

$115M

Series A · Oct 2025

Lila Sciences revenue

$75M

Series A · Oct 2025

Key investors in Lila Sciences

  • General Catalyst
  • March Capital
  • Flagship Pioneering
  • NVentures
  • Abu Dhabi Investment Authority
  • Altitude Life Science Ventures

Lila Sciences Overview

About Lila Sciences

Lila Sciences is a Boston-based AI platform accelerating discoveries in life sciences, chemistry, and materials. Its tools automate hypothesis generation, experiment design, and data analysis using large language models trained on 100 million publications. Deployed by 50 labs at universities like MIT, it integrates robotic labs for high-throughput synthesis.


Founded

2023

HQ

United StatesUnited States

Website

lila.ai

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Revenue

$75M (Oct 2025)

Valuation

$1.3B (Oct 2025)

Lila Sciences Valuation

Lila Sciences is currently valued at $1.3B, based on its Series A in October 2025.

The $115M round was led by NVentures.

Lila Sciences' valuation has moved from $1.3B at its seed round in March 2025 to $1.3B in October 2025, across 3 priced rounds.

Lila Sciences valuation by funding round

Revenue multiple
Lila Sciences valuation by funding round
DateStageValuationRevenue Multiple
Oct 2025Series A$1.3B17.3x
Sep 2025Series A$1.2B-
Mar 2025Seed$1.3B-

Lila Sciences Revenue

Lila Sciences' latest recorded revenue is $75M, as of its Series A in October 2025. At a $1.3B valuation, that implies a 17.3x revenue multiple.

Lila Sciences revenue by funding round

Lila Sciences revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Oct 2025$75M$1.3B17.3xSeries A

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Lila Sciences Funding History

Lila Sciences has raised a total of $550M across 3 funding rounds.

Lila Sciences' first fundraising round was a $200M seed round in March 2025. The most recent completed round was a $115M Series A in October 2025.

Lila Sciences funding rounds

Lila Sciences funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Oct 2025Series ANVentures (lead)$115M$1.3BLila Sciences, an AI startup originating from Flagship Pioneering, develops 'AI Science Factories'—autonomous labs powered by specialized AI models for continuous experimentation, analysis, and hypothesis generation in fields like life sciences, chemistry, materials, green energy, drug development, carbon capture, and semiconductors. The company positions its scientific superintelligence platform to accelerate discoveries, which partners and startups can commercialize rather than Lila developing products in-house. On October 14, 2025, Lila raised $115 million in a Series A extension led by NVIDIA's NVentures, with other participants including Analog Devices, In-Q-Tel, and Dauntless Ventures, bringing the total Series A to $350 million and overall funding to $550 million. This extension followed a prior $235 million Series A tranche co-led by Braidwell and Collective Global, with additional investors like General Catalyst, ADIA, and various institutional funds representing over $2 trillion in assets under management. The funding values Lila Sciences at over $1.3 billion post-money, highlighting strong investor interest in AI-driven scientific automation. The capital will expand operations, including a 235,500-square-foot lab lease in Cambridge, Massachusetts, and open the platform to commercial customers in energy, semiconductors, and drug development. Lila's automated labs have already generated thousands of discoveries across chemistry, materials, and life sciences, supported by collaborations providing cutting-edge computational infrastructure from partners like NVIDIA. The diverse investor syndicate spans biotech, deep tech, national security, and sovereign wealth funds, betting on AI's role in physical scientific systems and reindustrialization of critical technologies.
Sep 2025Series ABraidwell (lead); Collective Global Management (lead)$235M$1.2BLila Sciences, founded by Flagship Pioneering and led by CEO Geoffrey von Maltzahn, emerged from stealth in March 2025 with a $200 million seed round from investors including General Catalyst, March Capital, ARK Venture Fund, and others. The Massachusetts-based company is developing a scientific superintelligence platform that integrates generative AI, robotics, and automated labs to accelerate discoveries in life sciences, chemistry, materials, and beyond, enabling autonomous hypothesis generation, experiment design, and validation for applications like novel protein therapeutics, nucleic acids, and diagnostics to address challenges in cancer, obesity, and immune diseases. In September 2025, Lila Sciences raised a $235 million Series A round co-led by Braidwell and Collective Global Management, with participation from Altitude Life Science Ventures, ARK Investment Management, Alumni Ventures, Flagship Pioneering, General Catalyst, March Capital, the Mathers Foundation, Modi Ventures, NGS Super, State of Michigan Retirement System, and a subsidiary of Abu Dhabi Investment Authority, achieving a post-money valuation of approximately $1.23 billion and unicorn status. The funding supports expansion of its AI-driven research platform, workforce growth, and new hubs in San Francisco, Boston, and London to scale AI Science Factories for high-throughput experimentation. The Series A was later extended in October 2025 by $115 million from additional investors like NVentures and Catalio Capital Management, bringing the total Series A to $350 million and overall funding to $550 million, with valuation rising above $1.3 billion. Lila's platform aims to compress scientific timelines from days or weeks to minutes or hours, positioning it among the most heavily financed AI-life sciences ventures amid a market projected to grow from $2.88 billion to $8.8 billion by 2029. Key advisors include George Church as CSO and Andrew Beam as CTO, leveraging expertise in genetics and AI to build an operating system for autonomous science across therapeutics, materials, manufacturing, energy, and computing.
Mar 2025SeedFlagship Pioneering (lead); General Catalyst; Blue Horizon Advisors; Abu Dhabi Investment Authority; March Capital; ARK Venture Fund; Altitude Life Science Ventures; State of Michigan Retirement System; Modi Ventures$200M$1.3BLila Sciences is an artificial intelligence startup founded in 2023 by Flagship Pioneering with the mission of creating 'scientific superintelligence' through autonomous AI-driven research systems. The company integrates advanced AI with autonomous lab systems and robotics to accelerate scientific discovery across materials science, chemistry, and life sciences. Its core offering consists of 'AI Science Factories'—highly automated research environments designed to independently generate hypotheses, design and execute experiments, and rapidly learn from results without relying solely on historical literature or databases. In October 2025, Lila Sciences closed a $350 million Series A round that included multiple investors focused on deep tech and scientific advancement. This round was split into a $235 million tranche closed in September 2025 (led by Braidwell Capital and Collective Global) plus an additional $115 million extension in October 2025 with backing from Nvidia's venture arm. The combined Series A brought the company's post-money valuation to $1.3 billion and total capital raised to $550 million, including a $200 million seed round closed at launch in March 2023. Lila Sciences is using the capital to expand its AI Science Factories infrastructure, which are being constructed in Boston, London, and San Francisco. The company has secured a major real estate commitment, signing a 235,500-square-foot lease in Cambridge. Rather than developing products internally, Lila operates a platform model, licensing its autonomous research infrastructure and AI capabilities to partners in pharmaceuticals, energy, semiconductors, and materials discovery. The company claims its automated labs have already generated thousands of discoveries and developed advanced large language models with scientific reasoning capabilities, genetic medicine constructs, and novel antibodies and peptides, though independent verification has not been publicly released. The company's growth trajectory reflects strong investor confidence in AI-driven scientific automation as a critical infrastructure layer. Lila's positioning as a platform provider—dubbed 'the AWS of science'—diversifies revenue exposure compared to traditional biotech R&D models and creates a compounding data advantage as each experiment refines underlying AI models. The funding will accelerate deployment of the platform to commercial partners in what the company describes as strategic scientific domains.

Who has invested in Lila Sciences?

12 investors have backed Lila Sciences across its funding rounds, including General Catalyst, March Capital, Flagship Pioneering, NVentures, Abu Dhabi Investment Authority and Altitude Life Science Ventures.

Lead investors include NVentures, Braidwell, Collective Global Management and Flagship Pioneering.


Lila Sciences Investors

Investors in Lila Sciences by funding rounds participated
InvestorHQRoundsRoleFirst check
General CatalystUnited StatesSan Francisco, CA1ParticipantMar 2025
Collective Global ManagementUnited StatesNew York City, NY1LeadSep 2025
Flagship PioneeringUnited StatesUnited States1LeadMar 2025
NVenturesUnited StatesSan Jose, CA1LeadOct 2025
Blue Horizon AdvisorsGuernseySt. Peter Port1ParticipantMar 2025
Abu Dhabi Investment AuthorityUAEAbu Dhabi1ParticipantMar 2025
March CapitalUnited StatesLos Angeles, CA1ParticipantMar 2025
ARK Venture FundUnited StatesSan Francisco, CA1ParticipantMar 2025
BraidwellUnited StatesStamford, CT1LeadSep 2025
Altitude Life Science VenturesUnited StatesDurango, CO1ParticipantMar 2025

This data is available for Pro users. Sign up to see all 12 Lila Sciences investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Lila Sciences Competitors

Lila Sciences competitors include listed companies like VCANBIO and Fractal Analytics, and private ones like Pathos, Collate, AppZen and Deepgram.

Public and private companies comparable to Lila Sciences
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
PathosUnited StatesChicago, ILPrivate$13M$3M$1.6B123.1x
CollateUnited StatesSan Francisco, CAPrivate--$1B-
AppZenUnited StatesSan Jose, CAPrivate--$1.3B-
DeepgramUnited StatesUnited StatesPrivate$240M-$1.3B-
VCANBIOChinaChinaPublicly listed$217M$44M$1.3B4.3x
Fractal AnalyticsIndiaIndiaPublicly listed$344M$50M$1.3B3.4x

Lila Sciences Public Comps

Lila Sciences is still privately-owned, but its public comps include VCANBIO, Fractal Analytics, Sansure Biotech, PCITECH, SEEGENE, Absci, Syngene, Appier Group, Rackspace and Vazyme Biotech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
VCANBIO$217M$44M4.6x4.3x22.8x25.1x
Fractal Analytics$344M$50M3.7x3.4x25.8x21.0x
Sansure Biotech$245M$48M4.2x4.1x21.3x14.6x
PCITECH$1.5B$53M0.8x0.9x24.1x-
SEEGENE$345M$85M2.3x2.1x9.2x7.7x
Absci$3M($103M)496.8x388.4x(13.5x)(11.9x)
Syngene$376M$88M4.0x3.9x17.1x15.5x
Appier Group$281M$44M3.4x2.9x21.6x15.7x

This data is available for Pro users. Sign up to see all Lila Sciences competitors and their valuation data.

Start Free Trial

Common questions about Lila Sciences

When was Lila Sciences founded?Lila Sciences was founded in 2023.
Where is Lila Sciences headquartered?Lila Sciences is headquartered in United States.
Is Lila Sciences publicly listed?No, Lila Sciences is a private, VC-backed company.
What is Lila Sciences' valuation?Lila Sciences was last valued at $1.3B in its Series A in October 2025.
How much funding has Lila Sciences raised?Lila Sciences has raised $550M across 3 funding rounds.
What was Lila Sciences' last funding round?Lila Sciences' last funding round was a $115M Series A in October 2025, led by NVentures.
Who are Lila Sciences' investors?Lila Sciences' investors include General Catalyst, Collective Global Management, Flagship Pioneering, NVentures, Blue Horizon Advisors, Abu Dhabi Investment Authority, March Capital, ARK Venture Fund, Braidwell, Altitude Life Science Ventures and 2 others.
What is Lila Sciences' revenue?Lila Sciences' latest recorded revenue is $75M (October 2025).
What is Lila Sciences' revenue multiple?Lila Sciences' latest valuation implies a 17.3x revenue multiple ($1.3B valuation on $75M of revenue).
Which companies are comparable to Lila Sciences?Companies comparable to Lila Sciences include Pathos, Collate, AppZen, Deepgram, VCANBIO and Fractal Analytics.

See companies similar to Lila Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial